palmitic acid and Breast Neoplasms studies

Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.
hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.

Research Excerpts

Excerpt	Relevance	Reference
"Breast cancer is the most common malignant tumor in women, and the liver is the main target organ for breast cancer metastasis."	5.91	Palmitic acid-modified human serum albumin paclitaxel nanoparticles targeting tumor and macrophages against breast cancer. ( Fang, C; Feng, J; Gong, T; Li, J; Tan, Y; Wu, Q; Xiang, L; Zhou, X, 2023)
"Palmitic acid was the main compound responsible for this apoptotic effect by a ceramide-independent mechanism that involved endoplasmic reticulum (ER)-stress with upregulation of CCAAT/-enhancer-binding protein homologous protein (CHOP)."	5.39	Palmitic acid and ergosta-7,22-dien-3-ol contribute to the apoptotic effect and cell cycle arrest of an extract from Marthasterias glacialis L. in neuroblastoma cells. ( Andrade, PB; Correia-da-Silva, G; Pereira, DM; Teixeira, N; Valentão, P, 2013)
"As a reflection of SCD-1 activity, we measured the ratios of palmitoleic acid (C16:1n7) to palmitic acid (C16:0) (SCD-16) and oleic acid (C18:1n9) to steric acid (C18:0) (SCD-18) in plasma samples of postmenopausal women enrolled in our clinical trial (NCT00723398) designed to test the effects of the antiestrogen, Raloxifene and/or the omega-3 preparation Lovaza, on breast density, a validated biomarker of breast cancer risk."	5.24	Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women. ( Aliaga, C; Calcagnotto, A; El-Bayoumy, K; Manni, A; Richie, JP; Schetter, SE; Trushin, N, 2017)
"Breast cancer is the most common malignant tumor in women, and the liver is the main target organ for breast cancer metastasis."	1.91	Palmitic acid-modified human serum albumin paclitaxel nanoparticles targeting tumor and macrophages against breast cancer. ( Fang, C; Feng, J; Gong, T; Li, J; Tan, Y; Wu, Q; Xiang, L; Zhou, X, 2023)
"Therefore, two different breast cancer cell lines; triple negative breast cancer (TNBC; MDA-MB-231) and triple positive breast cancer (TPBC; BT-474) cells were used to examine such role."	1.46	Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis. ( Al-Abri, N; Al-Adawi, K; Al-Adawi, M; Al-Bahlani, S; Al-Dhahli, B; Al-Lawati, H, 2017)
"Palmitic acid was the main compound responsible for this apoptotic effect by a ceramide-independent mechanism that involved endoplasmic reticulum (ER)-stress with upregulation of CCAAT/-enhancer-binding protein homologous protein (CHOP)."	1.39	Palmitic acid and ergosta-7,22-dien-3-ol contribute to the apoptotic effect and cell cycle arrest of an extract from Marthasterias glacialis L. in neuroblastoma cells. ( Andrade, PB; Correia-da-Silva, G; Pereira, DM; Teixeira, N; Valentão, P, 2013)
"Fourteen breast cancer patients with a mean age of 61 years were recruited."	1.39	Carcinogenesis alters fatty acid profile in breast tissue. ( Azordegan, N; Fischer, G; Fraser, V; Hillyer, LM; Le, K; Ma, DW; Moghadasian, MH, 2013)
"The prognosis for women with breast cancer is adversely affected by the comorbidities of obesity and diabetes mellitus (DM), which are conditions associated with elevated levels of circulating fatty acids, hyperglycaemia and hyperinsulinaemia."	1.36	Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. ( Biernacka, KM; Foulstone, EJ; Holly, JM; Jarrett, C; Morgan, A; Morrison, AA; Perks, CM; Shield, JP; Winters, ZE; Zeng, L, 2010)
"While characterizing a drug-resistant breast cancer cell line, MCF7/AdVp3000, we found that fatty acid synthase (FASN) is overexpressed."	1.35	A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. ( Liu, H; Liu, Y; Zhang, JT, 2008)
"Transfection of ERalpha S522A into breast cancer cells that express native ER downregulated E2 binding at the membrane, signaling to ERK, and G1/S cell cycle events and progression."	1.32	Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. ( Alton, G; Ghonshani, S; Levin, ER; Pedram, A; Razandi, M; Webb, P, 2003)
"The human breast cancer cell line MCF7 does not express heart-type fatty acid binding protein (H-FABP), a marker protein for differentiated mammary gland."	1.30	Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. ( Börchers, T; Buhlmann, C; Pollak, M; Spener, F, 1999)
"We purified OA-519 from human breast carcinoma cells, obtained its peptide sequence, and unambiguously identified it as fatty acid synthase through sequence homology and enzymology."	1.29	Fatty acid synthesis: a potential selective target for antineoplastic therapy. ( Dick, JD; Hennigar, RA; Jacobs, LB; Jenner, K; Kuhajda, FP; Pasternack, GR; Wood, FD, 1994)

Research

Studies (27)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Absolute Breast Density

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (3.70)	18.7374
1990's	5 (18.52)	18.2507
2000's	10 (37.04)	29.6817
2010's	7 (25.93)	24.3611
2020's	4 (14.81)	2.80

Authors	Studies
Balunas, MJ	1
Su, B	1
Landini, S	1
Brueggemeier, RW	1
Kinghorn, AD	1
Liu, XZ	1
Rulina, A	1
Choi, MH	1
Pedersen, L	1
Lepland, J	1
Takle, ST	1
Madeleine, N	1
Peters, SD	1
Wogsland, CE	1
Grøndal, SM	1
Lorens, JB	1
Goodarzi, H	1
Lønning, PE	1
Knappskog, S	1
Molven, A	1
Halberg, N	1
He, Y	1
Rezaei, S	1
Júnior, RFA	1
Cruz, LJ	1
Eich, C	1
Xiang, L	1
Fang, C	1
Feng, J	1
Tan, Y	1
Wu, Q	1
Zhou, X	1
Li, J	1
Gong, T	1
Shen, L	1
Du, Y	1
Wei, N	1
Li, Q	1
Li, S	1
Sun, T	1
Xu, S	1
Wang, H	1
Man, X	1
Han, B	1
Al-Bahlani, S	1
Al-Lawati, H	1
Al-Adawi, M	1
Al-Abri, N	1
Al-Dhahli, B	1
Al-Adawi, K	1
Pereira, DM	1
Correia-da-Silva, G	1
Valentão, P	1
Teixeira, N	1
Andrade, PB	1
Abramczyk, H	1
Brozek-Pluska, B	1
Manni, A	1
Richie, JP	1
Schetter, SE	1
Calcagnotto, A	1
Trushin, N	1
Aliaga, C	1
El-Bayoumy, K	1
Jain, V	1
Nath, B	1
Gupta, GK	1
Shah, PP	1
Siddiqui, MA	1
Pant, AB	1
Mishra, PR	1
Zeng, L	1
Biernacka, KM	1
Holly, JM	1
Jarrett, C	1
Morrison, AA	1
Morgan, A	1
Winters, ZE	1
Foulstone, EJ	1
Shield, JP	1
Perks, CM	1
Licciardi, M	1
Cavallaro, G	1
Di Stefano, M	1
Pitarresi, G	1
Fiorica, C	1
Giammona, G	1
Azordegan, N	1
Fraser, V	1
Le, K	1
Hillyer, LM	1
Ma, DW	1
Fischer, G	1
Moghadasian, MH	1
Shabbits, JA	1
Mayer, LD	1
Razandi, M	1
Alton, G	1
Pedram, A	1
Ghonshani, S	1
Webb, P	1
Levin, ER	1
Rai, D	1
Frolova, A	1
Frasor, J	1
Carpenter, AE	1
Katzenellenbogen, BS	1
Chajès, V	2
Cambot, M	1
Moreau, K	1
Lenoir, GM	1
Joulin, V	1
Draghici, S	1
Khatri, P	1
Tarca, AL	1
Amin, K	1
Done, A	1
Voichita, C	1
Georgescu, C	1
Romero, R	1
Chiang, CT	1
Way, TD	1
Tsai, SJ	1
Lin, JK	1
Liu, H	1
Liu, Y	1
Zhang, JT	1
Itoh, K	1
Nakamura, M	1
Akino, T	1
Kuhajda, FP	1
Jenner, K	1
Wood, FD	1
Hennigar, RA	1
Jacobs, LB	1
Dick, JD	1
Pasternack, GR	1
Ammer, H	1
Schulz, R	1
Takahashi, N	1
Iwahori, A	1
Breitman, TR	1
Fukui, T	1
Hultén, K	1
Van Kappel, AL	1
Winkvist, A	1
Kaaks, R	1
Hallmans, G	1
Lenner, P	1
Riboli, E	1
Buhlmann, C	1
Börchers, T	1
Pollak, M	1
Spener, F	1
Hardy, S	1
Langelier, Y	1
Prentki, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer[NCT00723398]		266 participants (Actual)	Interventional	2009-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change of absolute breast density as indicated by mammography from baseline to Year +1 and completion of study (Year +2). No other mammograms will be obtained or used for the purpose of this study. Absolute breast density volume is based on breast thickness and the x-ray attenuation at each pixel of the image. (NCT00723398)
Timeframe: 2 years

Changes in Biomarkers for Estrogen Metabolism: 2-hydroxy Estrone (Urinary 2-OHE1) and 16-α-hydroxy Estrone (16α-OHE1)

Intervention	cm squared (Mean)
	Absolute density at baseline	Absolute density at 1 year	Absolute density at 2 years
Group 1: Control	65.53	59.29	54.34
Group 2: Raloxifene 60 mg	64.39	60.48	60.57
Group 3: Raloxifene 30 mg	65.08	59.53	58.86
Group 4: Lovaza 4 gm	56.35	58.87	57.60
Group 5: Lovaza 4 gm and Raloxifene 30 mg	63.81	60.93	28.53

Changes in biomarkers for estrogen metabolism: 2-hydroxy estrone (Urinary 2-OHE1) and 16-α-hydroxy estrone (16α-OHE1) as measured by urinary analysis. Specific time points for evaluation are baseline and Year +1 (only). (NCT00723398)
Timeframe: 1 year

Changes in Biomarkers for Oxidative Stress: Urinary 8-hydroxy-deoxyguansine

Intervention	ng/mg creatinine (Mean)
	Baseline: Urinary 2-OHE1	1 year: Urinary 2-OHE1	Baseline: 16α-OHE1	1 year: 16α-OHE1
Group 1: Control	10.57	7.46	6.22	5.68
Group 2: Raloxifene 60 mg	8.58	10.03	5.08	4.35
Group 3: Raloxifene 30 mg	8.82	9.10	6.86	7.46
Group 4: Lovaza 4 gm	7.15	7.49	5.24	4.79
Group 5: Lovaza 4 gm and Raloxifene 30 mg	15.6	13.2	6.6	5.68

Changes in biomarkers for oxidative stress. Specific time points for evaluation are baseline and Year +1 (only). Urinary 8-hydroxy-deoxyguansine as measured through urinary analysis. (NCT00723398)
Timeframe: 1 year

Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2α

Intervention	ng/mg creatinine (Mean)
	Baseline	1 year
Group 1: Control	255	224
Group 2: Raloxifene 60 mg	285	309
Group 3: Raloxifene 30 mg	213	246
Group 4: Lovaza 4 gm	184	177
Group 5: Lovaza 4 gm and Raloxifene 30 mg	355	297

Changes in biomarkers for oxidative stress. Specific time points for evaluation are baseline and Year +1 (only). Urinary 8-(isoprostane) F-2α as measured through urine analysis. (NCT00723398)
Timeframe: 1 year

Changes in Complete Blood Count: Hematocrit

Intervention	pg/mg creatinine (Mean)
	Baseline	1 year
Group 1: Control	544	484
Group 2: Raloxifene 60 mg	366	360
Group 3: Raloxifene 30 mg	530	538
Group 4: Lovaza 4 gm	440	313
Group 5: Lovaza 4 gm and Raloxifene 30 mg	444	396

Changes in complete blood count levels as measured through hematocrit percentage. Specific time points for evaluation are baseline, Year +1, and Year 2. (NCT00723398)
Timeframe: 2 years

Changes in Complete Blood Count: Hemoglobin

Intervention	volume percentage (Mean)
	Baseline: Hematocrit	1 year: Hematocrit	2 year: Hematocrit
Group 1: Control	39.14	38.83	39.00
Group 2: Raloxifene 60 mg	38.95	38.79	38.86
Group 3: Raloxifene 30 mg	38.79	38.43	38.31
Group 4: Lovaza 4 gm	39.09	39.52	38.59
Group 5: Lovaza 4 gm and Raloxifene 30 mg	39.20	39.14	39.14

Changes in complete blood count levels as measured through hemoglobin. Specific time points for evaluation are baseline, Year +1, and Year 2. (NCT00723398)
Timeframe: 2 years

Changes in Complete Blood Count: Red Blood Cells

Intervention	g/dL (Mean)
	Baseline: Hemoglobin	1 year: Hemoglobin	2 year: Hemoglobin
Group 1: Control	13.09	12.97	13.10
Group 2: Raloxifene 60 mg	13.11	12.97	13.07
Group 3: Raloxifene 30 mg	12.73	12.95	12.82
Group 4: Lovaza 4 gm	13.25	13.33	13.16
Group 5: Lovaza 4 gm and Raloxifene 30 mg	13.35	13.10	13.22

Changes in complete blood count levels as measured through red blood cells (RBC). Specific time points for evaluation are baseline, Year +1, and Year 2. (NCT00723398)
Timeframe: 2 years

Changes in Complete Blood Count: White Blood Cells and Platelets

Intervention	millions of cells per microliter (Mean)
	Baseline: RBC	1 year: RBC	2 year: RBC
Group 1: Control	4.31	4.27	4.32
Group 2: Raloxifene 60 mg	4.25	4.19	4.20
Group 3: Raloxifene 30 mg	4.30	4.25	4.24
Group 4: Lovaza 4 gm	4.33	4.36	4.33
Group 5: Lovaza 4 gm and Raloxifene 30 mg	4.24	4.20	4.23

Changes in complete blood count levels as measured through white blood cells (WBC) and platelets. Specific time points for evaluation are baseline, Year +1, and Year 2. (NCT00723398)
Timeframe: 2 years

Changes in Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor-1 Binding Protein-3 (IGFBP-3)

Intervention	thousand cells/mL (Mean)
	Baseline: WBC	1 year: WBC	2 year: WBC	Baseline: Platelets	1 year: Platelets	2 year: Platelets
Group 1: Control	5.13	5.15	5.14	270.70	237.02	234.02
Group 2: Raloxifene 60 mg	5.47	5.51	5.42	235.22	228.02	226.16
Group 3: Raloxifene 30 mg	5.00	4.78	4.90	240.42	230.61	232.09
Group 4: Lovaza 4 gm	5.04	4.95	4.90	237.33	231.42	232.47
Group 5: Lovaza 4 gm and Raloxifene 30 mg	5.27	4.91	4.91	235.76	221.49	223.27

Changes in insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-1 binding protein-3 (IGFBP-3) obtained through blood sample. Specific time points for evaluation are baseline and Year +1 (only). (NCT00723398)
Timeframe: 1 year

Changes in Serum Biomarkers for Inflammation From Levels of High Sensitivity C-reactive Protein (hsCRP) and Interleukin 6 (IL-6)

Intervention	ng/mL (Mean)
	Baseline: IGF-1	1 year: IGF-1	Baseline: IGFBP-3	1 year: IGFBP-3
Group 1: Control	4.96	5.05	7.67	7.75
Group 2: Raloxifene 60 mg	4.63	4.40	7.53	7.55
Group 3: Raloxifene 30 mg	4.80	4.76	7.69	7.79
Group 4: Lovaza 4 gm	4.95	4.96	7.83	7.83
Group 5: Lovaza 4 gm and Raloxifene 30 mg	4.89	4.82	7.57	7.61

Changes in serum biomarkers for inflammation including highly sensitive C-reactive protein and IL-6 obtained through a blood draw. Specific time points for evaluation are baseline and Year +1 (only). (NCT00723398)
Timeframe: 1 Year

Changes in Serum Lipid Levels

Intervention	pg/ml (Mean)
	Baseline: Serum hsCRP	1 year: Serum hsCRP	Baseline: Serum IL-6	1 year: Serum IL-6
Group 1: Control	2.39	2.19	1.27	1.03
Group 2: Raloxifene 60 mg	0.91	1.04	1.14	1.13
Group 3: Raloxifene 30 mg	1.67	1.34	1.04	1.11
Group 4: Lovaza 4 gm	1.22	1.69	1.32	1.49
Group 5: Lovaza 4 gm and Raloxifene 30 mg	4.28	2.59	1.84	1.32

Changes in serum lipid levels as measured through total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. Specific time points for evaluation are baseline, Year +1, and Year 2. (NCT00723398)
Timeframe: 2 years

Intervention	mg/dL (Mean)
	Baseline: Total Cholesterol	1 year: Total Cholestrol	2 year: Total Cholesterol	Baseline: LDL Cholesterol	1 year: LDL Cholesterol	2 year: LDL Cholesterol	Baseline: HDL Cholesterol	1 year: HDL Cholesterol	2 year: HDL Cholestrol	Baseline: Triglycerides	1 year: Triglycerides	2 year: Triglycerides
Group 1: Control	207.3	208.8	207.5	114	115.1	115.3	68.75	70.71	70.19	122.7	114.5	110.1
Group 2: Raloxifene 60 mg	203.6	198.3	196.6	114.7	106.8	104.7	66.18	68.88	68.63	113.2	113.2	116.9
Group 3: Raloxifene 30 mg	204.3	199.6	202.3	111.2	106.2	106.1	70.92	70.59	73.17	110.6	113.7	115.8
Group 4: Lovaza 4 gm	197.7	199.6	200.2	106.6	109.7	110.4	68.06	70.59	70.67	115.1	96.22	95.41
Group 5: Lovaza 4 gm and Raloxifene 30 mg	197.6	189.4	192.6	108.1	96.58	99.48	68.9	76.11	75.77	103.6	83.71	86.43

Article	Year
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. Journal of natural products, 2006, Volume: 69, Issue:4 Topics: Aromatase; Biological Products; Breast Neoplasms; Fatty Acids; Female; Humans; Microsomes; Placenta;	2006
C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. Nature communications, 2022, 01-10, Volume: 13, Issue:1 Topics: Adult; Aged; Animals; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Epige	2022
Multifunctional Role of Lipids in Modulating the Tumorigenic Properties of 4T1 Breast Cancer Cells. International journal of molecular sciences, 2022, Apr-11, Volume: 23, Issue:8 Topics: Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Ceramides; Epithelial-Mesenchymal Transition; Fe	2022
Palmitic acid-modified human serum albumin paclitaxel nanoparticles targeting tumor and macrophages against breast cancer. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2023, Volume: 183 Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Liver Neoplasms; Macrophages; Nanoparticles; Pac	2023
SERS studies on normal epithelial and cancer cells derived from clinical breast cancer specimens. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2020, Aug-15, Volume: 237 Topics: Adipose Tissue; Adult; Aged; Algorithms; Breast Neoplasms; Cholesterol; Epithelial Cells; Female; Fl	2020
Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis. Apoptosis : an international journal on programmed cell death, 2017, Volume: 22, Issue:6 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Down-Regulation; Fatty Acid Synthases; Fem	2017
Palmitic acid and ergosta-7,22-dien-3-ol contribute to the apoptotic effect and cell cycle arrest of an extract from Marthasterias glacialis L. in neuroblastoma cells. Marine drugs, 2013, Dec-24, Volume: 12, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Blotting, Western; Breast Neoplasms;	2013
New look inside human breast ducts with Raman imaging. Raman candidates as diagnostic markers for breast cancer prognosis: Mammaglobin, palmitic acid and sphingomyelin. Analytica chimica acta, 2016, Feb-25, Volume: 909 Topics: Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Mammaglobin A; Palmi	2016
Galactose-grafted chylomicron-mimicking emulsion: evaluation of specificity against HepG-2 and MCF-7 cell lines. The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Asialoglycoprotein Receptor; Breast Neoplasms; Carcinoma, Hepatoc	2009
Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocrine-related cancer, 2010, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Death; Ceramides; Drug Evaluation, Preclini	2010
New self-assembling polyaspartylhydrazide copolymer micelles for anticancer drug delivery. International journal of pharmaceutics, 2010, Aug-30, Volume: 396, Issue:1-2 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical;	2010
Carcinogenesis alters fatty acid profile in breast tissue. Molecular and cellular biochemistry, 2013, Volume: 374, Issue:1-2 Topics: Arachidonic Acid; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Transformation, Neoplast	2013
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Molecular cancer therapeutics, 2002, Volume: 1, Issue:3 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Ce	2002
Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Molecular and cellular biology, 2003, Volume: 23, Issue:5 Topics: Animals; Binding, Competitive; Breast Neoplasms; Caveolin 1; Caveolins; Cell Cycle; Cell Membrane; C	2003
Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. Molecular endocrinology (Baltimore, Md.), 2005, Volume: 19, Issue:6 Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Nucleus; Cell Proliferati	2005
Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer research, 2006, May-15, Volume: 66, Issue:10 Topics: Acetyl-CoA Carboxylase; Apoptosis; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Fatty	2006
A systems biology approach for pathway level analysis. Genome research, 2007, Volume: 17, Issue:10 Topics: Adenocarcinoma; Blood Coagulation; Breast Neoplasms; Cell Line; Complement Activation; Databases, Ge	2007
Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS letters, 2007, Dec-22, Volume: 581, Issue:30 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diosgenin;	2007
A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Molecular cancer therapeutics, 2008, Volume: 7, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Drug Resist	2008
Comparison of phospholipid profiles of primary adenocarcinoma in the lung and other organs. Lipids, 1981, Volume: 16, Issue:12 Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Fatty Acids; Humans; Lung Neoplasms; Palmitic A	1981
Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proceedings of the National Academy of Sciences of the United States of America, 1994, Jul-05, Volume: 91, Issue:14 Topics: Acetates; Antibodies; Antigens, Neoplasm; Biomarkers, Tumor; Blood Proteins; Breast Neoplasms; Carbo	1994
Enhanced stimulatory adenylyl cyclase signaling during opioid dependence is associated with a reduction in palmitoylated Gs alpha. Molecular pharmacology, 1997, Volume: 52, Issue:6 Topics: Adenylyl Cyclases; Animals; Breast Neoplasms; Carcinoma, Squamous Cell; GTP-Binding Protein alpha Su	1997
Tunicamycin in combination with retinoic acid synergistically inhibits cell growth while decreasing palmitoylation and enhancing retinoylation of proteins in the human breast cancer cell line MCF-7. Oncology research, 1997, Volume: 9, Issue:10 Topics: Acylation; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Drug Syn	1997
Fatty-acid composition in serum phospholipids and risk of breast cancer: an incident case-control study in Sweden. International journal of cancer, 1999, Nov-26, Volume: 83, Issue:5 Topics: Breast Neoplasms; Case-Control Studies; Fatty Acids, Unsaturated; Female; Humans; Incidence; Middle	1999
Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. Molecular and cellular biochemistry, 1999, Volume: 199, Issue:1-2 Topics: Animals; Breast Neoplasms; Carbon Radioisotopes; Carrier Proteins; Cattle; Enzyme-Linked Immunosorbe	1999
Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer research, 2000, Nov-15, Volume: 60, Issue:22 Topics: Apoptosis; Breast Neoplasms; Cell Division; Culture Media, Serum-Free; Drug Interactions; Enzyme Act	2000

palmitic acid and Breast Neoplasms